Should The NICE Cost-Effectiveness Range Be Lowered?

This question goes to the heart of the use of the cost per quality-adjusted life-year (QALY) in healthcare decision making. Download or View Article here. (Source: J.P. Raftery, University of Southhampton, 5/9/14).

You might also be interested in:

CVS Caremark’s Foray into Cost-Effectiveness Analysis… September 25, 2018
ICER Report: HAE Treatments Yield Health Improvements, but at… October 14, 2018
eDossier System to Offer hēRo3 Model Integration November 8, 2018
CVS Caremark Pushes Forward with QALYs Despite Patient… December 3, 2018
Opinion: Abandon QALY Metric in Cost-Effectiveness Reviews February 22, 2019
Analysis Looks at How ICER’s QALYs Could Impact Pricing in U.S. September 23, 2018
CVS Health Execs Respond to NPC’s Criticism of New Program September 18, 2018